We were delighted to speak to Ihsane Hmamouchi regarding the use of clomipramine for the treatment of chronic lumbar radicular pain. The abstract ‘Efficacy of Clomipramine for Chronic Lumbar Radicular Pain a Randomized Clinical Trial’ (ABSTRACT NUMBER: 0962) was presented at the virtual ACR Convergence 2020, 5-9 November 2020.
- What is the rationale for the use of clomipramine for chronic lumbar radicular pain? (0:27)
- What were the aims and design of the recent clinical trial you are presenting? (1:40)
- What were the efficacy and safety findings of this study? (4:25)
- What are the implications of these findings for future clinical practice? (6:10)
- What factors should clinicians consider when prescribing clomipramine in this treatment setting? (6:51)
Disclosures: Ihsane Hmamouchi has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the ACR 2020 Annual Meeting (Virtual).
Share this Video
Related Videos In Rheumatic Diseases
Nicholas Harvey, WCO21: The Royal Osteoporosis Society Research Roadmap
touchIMMUNOLOGY joins Professor Nicholas Harvey (University of Southampton, UK) at WCO21 to discuss the aims and hopes of the Royal Osteoporosis Society’s Research Roadmap initiative. Questions 1. What are the current unmet needs in osteoporosis and bone research? (00:27-01:26) 2. Please can you provide a short summary of the main aims of the Osteoporosis and […]
Emma Clark, WCO21: Novel Technologies for Skeletal Assessment
touchIMMUNOLOGY joins Professor Emma Clark (University of Bristol, UK) at WCO21 to discuss the current limitations of osteoporosis diagnosis and the latest novel technologies for skeletal assessment. Questions 1. Why is the diagnosis of osteoporosis so challenging? (00:16-02:13) 2. What are the strengths and limitations of currently available tools and services to diagnose osteoporosis? (02:13-04:28) […]
Philip Conaghan, WCO21: Tanezumab in the Treatment of Patients with Moderate-to-severe Osteoarthritis
touchIMMUNOLOGY joins Professor Philip Conaghan (University of Leeds, UK) at WCO21 to discuss improvements in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and use of tanezumab in the treatment of patients with moderate-to-severe osteoarthritis. Questions 1. What is the rationale for the use of tanezumab in the treatment of patients with moderate-to-severe osteoarthritis? […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!